尤瑞克林联合醒脑静治疗急性脑梗塞对患者神经功能的影响

郭靖　安晓雷　李晓宾　欧春影　许可

[摘要] 目的 分析尤瑞克林聯合醒脑静治疗急性脑梗塞对患者神经功能的影响。 方法 方便选择2017年2月—2018年2月，医院神经内科收治的急性脑梗塞患者80例，按照入院顺序分组，对照组、观察组各入组40例，均给予基础抗血小板、降血脂等基础治疗，对照组尤瑞克林，观察组联合醒脑静。 结果 观察组2周后、8周后、卒中90 d的NIHSS评分分别为（6.3±1.2）分、（4.0±2.1）分、（1.9±1.1）分低于对照组（7.7±1.5）分、（5.5±1.7）分、（3.1±1.0）分，差异有统计学意义（t=4.609、3.511、5.105，P=0.000、0.001、0.000<0.05）。观察组与对照组2周后LPA分别为（2.2±0.7）μmol/L、（2.8±0.8）μmol/L低于治疗前（3.7±1.1）μmol/L、（3.6±1.3）μmol/L（t=7.266、3.315，P=0.000、0.001）、观察组低于对照组（t=3.570、P=0.001），观察组与对照组卒中90 d的认知功能量表评分分别为（27.4±2.6）分、（25.0±4.1）分高于2周时（24.1±2.4）分、（22.3±2.0）分（t=5.899、3.743，P=0.000、0.000）、观察组高于对照组（t=3.127、0.002），差异有统计学意义（P<0.05）。观察组认知、精神相关并发症发生率15.0%低于对照组37.5%，差异有统计学意义（χ2=5.230，P=0.022<0.05）。结论尤瑞克林联合醒脑静治疗急性脑梗塞可以减轻神经功能损伤。

[关键词] 急性脑梗塞;神经功能;尤瑞克林;醒脑静

[中图分类号] R743.3          [文献标识码] A          [文章编号] 1674-0742（2019）07（a）-0106-03

Effect of Ureklin Combined with Xingnaojing on Neurological Function in Patients with Acute Cerebral Infarction

GUO Jing， AN Xiao-lei， LI Xiao-bin， OU Chun-ying， XU Ke

Department of Neurology， Xuzhou Central Hospital， Xuzhou， Jiangsu Province， 221000 China

[Abstract] Objective To analyze the effect of Ureklin combined with Xingnaojing on the neurological function of patients with acute cerebral infarction. Methods From February 2017 to February 2018， 80 patients with acute cerebral infarction admitted to the Department of Neurology of the hospital were convenient divided into two groups according to the order of admission. The control group and the observation group were each enrolled of 40 cases， all of which were given basic antiplatelet and blood lipid lowering treatment， the control group of Ureklin， the observation group combined with awakening brain. Results The NIHSS scores of the observation group were （6.3±1.2）points， （4.0±2.1）points， and （1.9±1.1）points lower than the control group （7.7±1.5）points， （5.5±1.7）points， （3.1±1.0） points after 2 weeks， 8 weeks， and 90 days of stroke， the difference was statistically significant （t=4.609， 3.511， 5.105， P=0.000， 0.001， 0.000<0.05）. After 2 weeks in the observation group and the control group， LPA was （2.2±0.7） μmol/L and （2.8±0.8） μmol/L， respectively， lower than （3.7±1.1） μmol/L and （3.6±1.3） μmol/L before treatment （t=7.266， 3.315， P=0.000， 0.001）， the observation group was lower than the control group （t=3.570， P=0.001）， and the cognitive function scale scores of the observation group and the control group were 90 days （27.4±2.6）points，（25.0±4.1）points points higher than 2 weeks （24.1 ± 2.4） points， （22.3±2.0） points （t=5.899， 3.743， P=0.000， 0.000）， the observation group was higher than the control group （t=3.127， 0.002）， the difference was statistically significant （P<0.05）. The incidence of cognitive and mental-related complications in the observation group was 15.0% lower than that in the control group （37.5%）， and the difference was statistically significant （χ2=5.230， P=0.022<0.05）. Conclusion Ureklin combined with Xingnaojing can reduce neurological damage by treating acute cerebral infarction.